title: [The absolute bioavailability of benzimidazole derivative RU-1205 in rats].
abstract: Pharmacokinetics of morpholinoethylimidazobenzimidazole derivative RU-1205 with kappa-agonist activity have been studied. The pharmacokinetic parameters were determined upon intravenous (10 mg/kg), peroral, and subcutaneous (50 mg/kg) administration. It is established that RU-1205 substance has high bioavailability (44.17 and 56.03% upon peroral and subcutaneous introduction, respectively).
authors.forename: A A
authors.initials: AA
authors.lastname: Spasov
authors.forename: L A
authors.initials: LA
authors.lastname: Smirnova
authors.forename: A I
authors.initials: AI
authors.lastname: Rashchenko
authors.forename: K A
authors.initials: KA
authors.lastname: Kuznetsov
authors.forename: V A
authors.initials: VA
authors.lastname: Anisimova
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats
chemical_list: C586860:9-(2-morpholinoethyl)-2-(4-fluorophenyl)imidazo(1,2-alpha)benzimidazole; D001562:Benzimidazoles; D009025:Morpholines